Carbon-14 radiosynthesis of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl) -6-(trifluoromethyl)-[4-14C]quinolin-2(1H)-one (XEN-D0401), a novel BK channel activator

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 53, Issue 3, 2010, Pages 140-146

  Kitson, Sean L ^a   Jones, Stuart ^a   Watters, William ^a   Chan, Fiona ^b   Madge, David ^b  

^a Almac Sciences   (United Kingdom)

^b Xention Limited   (United Kingdom)

Author keywords

3 substituted 4 arylquinolin 2(1H) one; BK channel activator; BMS 223131; Carbon 14; Overactive bladder (OAB)

Indexed keywords

CARBON; REACTION INTERMEDIATES;

3-SUBSTITUTED-4-ARYLQUINOLINE-2(1H)-ONE; BK CHANNEL ACTIVATOR; BK-CHANNEL; BMS-223131; CARBON 14; METHOXYMETHYL; ORTHO-LITHIATION; OVERACTIVE BLADDER; RADIOSYNTHESIS; TRIFLUOROMETHYL;

BENZOIC ACID;

4 (5 CHLORO 2 HYDROXYPHENYL) 3 (2 HYDROXYETHYL) 6 (TRIFLUOROMETHYL)QUINOLIN 2(1H) ONE C 14; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; XEN D 0401;

ARTICLE; DRUG PURIFICATION; DRUG SYNTHESIS; ISOTOPE LABELING; RADIOCHEMISTRY; REACTION ANALYSIS;

EID: 77950453679     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.1740     Document Type: Article

References (10)

1. E. S. Hamanaka, 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents, US 5,565,472, 1996. Available from: www. freepatentsonline.com/5565472.html.
2. P. Hewawasam, J. E. Starrett, S. G. Swartz, 4-aryl-3-aminoquinoline-2- one derivatives as potassium channel modulators, US 5,972,961, 1999. Available from: www.freepatentsonline.com/5972961.html.
3. Xention Limited, Investigational Medicinal Product Dossier XEN-D0401-CL-02 IMPD: XEN-D0401 Phase Ib Clinical Studies, Cambridge, UK, 2007.
4. Xention Limited, Fact Sheet-Overactive Bladder, Available from: http://www.xention.com/wp-content/uploads/Fact-sheet-Overactivebladder. pdf, 2009 [Friday 11 September 2009].
5. J. Wang, R. P. Discordia, G. A. Crispino, J. Li, J. A. Grosso, R. Polniaszek, V. C. Truc, Tetrahedron Lett. 2003, 44, 4271-4273.
6. D. V. Sivarao, K. Newberry, S. Langdon, A. V. Lee, P. Hewawasam, M. J. Plym, L. Signor, R. Myers, N. J. Lodge, J. Pharmacol. Exp. Ther. 2005, 313, 840-847.
7. E. L. Elliott, S. M. Bushell, M. Cavero, B. Tolan, T. R. Kelly, Org. Lett. 2005, 7, 2449-2451.
8. P. J. Kocieński, Protecting Groups, 3rd ed, Thieme, New York, 2005.
9. J. I. Ubeda, M. Villacampa, C. Avendano, Synthesis 1998, 1176-1180.
10. V. M. Vrudhula, B. Dasgupta, J. Qian-Cutrone, E. S. Kozlowski, C. G. Boissard, S. I. Dworetzky, D. Wu, Q. Gao, R. Kimura, V. K. Gribkoff, J. E. Starrett, J. Med. Chem. 2007, 50, 1050-1057.